|
Investors are believing the story OvaScience is telling of the potential of its treatments to help women with fertility challenges conceive. The company launched its Augment treatment, based on the platform technology of EggPC cells, at certain in vitro fertility clinics overseas in 2014. The company is also developing other next-generation treatments.
Last year, the Massachusetts company's share price jumped 384%, to $44.22 from $9.14 at the end of 2013. As a result, the company added $909 million to its market cap.
|
  |
0 comments
Hide comments
